Pharma Innovations: Vaccine Hesitancy and Biotech Breakthroughs

Mon Jan 26 2026

Summary

Podcast Summary: Pharma Innovations – Vaccine Hesitancy and Biotech Breakthroughs

Podcast: Pharma and BioTech Daily
Episode Date: January 26, 2026
Host: Pharma and BioTech News

Episode Overview

This episode centers on the pivotal innovations, challenges, and investment trends shaping the pharmaceutical and biotech industries in early 2026. The discussion highlights the growing influence of vaccine hesitancy, major funding rounds, breakthroughs in drug development, significant regulatory developments, and strategic corporate moves across the sector.

Key Discussion Points & Insights

1. Vaccine Hesitancy & Industry Impact

[00:19–02:00]

Moderna Halts Late-Stage Vaccine Trials:
- Moderna’s CEO, Stefan Bansal, cites both “shifts in government policy and increasing public skepticism towards vaccines” as reasons for pausing trials.
- This signals a “potential slowdown in vaccine research and development investments across the industry.”
Broader Implications:
- Public health initiatives and future pandemic preparedness may be at risk.
- Growing skepticism could alter the pace of innovation and resource allocation for vaccine R&D.
Quote:
- “This development signals a potential slowdown in vaccine research and development investments across the industry.” (Host, 00:40)

2. Mixed Results and Uncertainties in Drug Development

[02:00–03:00]

Sanofi’s Eczema Treatment – OX40 Blocker:
- Despite advancing towards FDA approval post-COAST 2 trial, results were “mixed, echoing earlier data that analysts found underwhelming.”
- Raises concerns about market potential and underscores the challenges of innovation in high-need therapeutic areas like dermatology.
Quote:
- “The broader industry is reminded of the complexities involved in bringing new therapies to market.” (Host, 02:45)

3. Biotech Funding and the GLP1 Therapy Race

[03:00–04:00]

Corexyl Secures $287M in Series D1 Funding:
- Focus on advancing oral GLP1 therapy in the US, prepping for Phase 3.
- Signals “robust interest” in GLP1 class for type 2 diabetes and obesity.
Competitive Landscape:
- Novo Nordisk’s Oral Wegovy progressing; Eli Lilly’s orforglipron faces delays.
- Market rewards timely development and novel delivery methods.

4. Regulatory Shifts: Rare Pediatric Disease Voucher Program

[04:00–04:45]

Failure to reauthorize the FDA’s Rare Pediatric Disease Priority Review Voucher program for 2024.
Advocates urge reinstatement, pointing to this program’s importance in fostering rare disease innovation.
Quote:
- “Such regulatory changes underscore the delicate balance between encouraging innovation and ensuring rigorous standards.” (Host, 04:30)

5. Oncology Investments and Tumor-Activated Drugs

[04:45–05:30]

Bristol Myers Squibb’s $850M in Janix Therapeutics:
- Underscores commitment to pioneering targeted oncology therapies.
- Reflects industry priority for precision medicine and reduced side effects.

6. Manufacturing & Biologics Expansion

[05:30–06:30]

Lott Biologics’ Syracuse ADC Hub (Launching 2026):
- Boost in global biological manufacturing capacity and quality.
Samsung Biologics – Profit Milestone:
- First Korean biopharma to surpass 2 trillion won profit.
- Emphasizes the ascendancy and influence of contract manufacturers.

7. Biosimilars: The Next Decade

[06:30–07:00]

Sandoz Eyes $322B Market:
- As biologic patents expire, biosimilars offer unprecedented opportunities for affordable access and market growth.

8. Precision Medicine and Companion Diagnostics

[07:00–07:20]

Gardent Health & Pfizer – FDA Approval for Gardent360:
- Diagnostic for BRAF V600E mutations in metastatic colorectal cancer.
- Advances in personalized oncology care driven by genetic profiling.

9. Global Vaccine Manufacturing Collaborations

[07:20–07:45]

CEPI, Merck, SK Bioscience's $30M Project (Ebola):
- Example of alliances pooling resources and expertise to expedite vaccine manufacturing.
Quote:
- “Such alliances harness collective expertise and resources to accelerate vaccine development.” (Host, 07:40)

10. Recent Clinical Trial Highlights

[07:45–08:30]

Corcept’s Relicoralent (Ovarian Cancer):
- Phase 3 shows overall survival benefit for platinum-resistant patients.
Hough Therapeutics HT001:
- Positive Phase 2 results for EGFR inhibitor-induced skin toxicities.

11. Investment Momentum & Strategic Expansions

[08:30–09:15]

Corexyl (Obesity), Pac Therapeutics (Crass-driven cancer therapy):
- Major funding rounds reflect confidence in emerging approaches.
W Medicine’s Dorzaliad (Diabetes):
- Expansion beyond China to wider Asian markets to address metabolic diseases.

12. Summary: The Dynamic Future of Biotech and Pharma

[09:15–end]

The episode concludes by highlighting:
- “A dynamic pharmaceutical and biotech landscape characterized by scientific breakthroughs, regulatory shifts, increased competition from biosimilars, and strategic collaborations.”
- Each advancement holds the promise of “better health outcomes worldwide.”

Notable Quotes & Memorable Moments

On Vaccine Hesitancy:
- “Moderna’s CEO Stefan Bansal pointed to shifts in government policy and an increasing public skepticism towards vaccines as pivotal reasons for this decision.” (00:36)
On Rare Disease Incentives:
- “Advocates are calling for its reinstatement given its critical role in incentivizing the development of rare disease treatments.” (04:15)
On Precision Medicine:
- “This approval emphasizes the critical role of precision diagnostics in personalizing cancer treatment regimens based on genetic profiles.” (07:14)
On Global Collaboration:
- “Such alliances harness collective expertise and resources to accelerate vaccine development.” (07:40)

Useful Timestamps

Vaccine Hesitancy & Moderna’s Trials: 00:19–02:00
Sanofi’s Eczema Drug Developments: 02:00–03:00
Corexyl's Funding & GLP1 Race: 03:00–04:00
FDA Rare Disease Program Update: 04:00–04:45
Bristol Myers & Janix Investment: 04:45–05:30
Manufacturing & Biologics Milestones: 05:30–06:30
Biosimilars Industry Forecast: 06:30–07:00
Precision Medicine Advances: 07:00–07:20
Ebola Vaccine Collaboration: 07:20–07:45
Clinical Trial Updates: 07:45–08:30
Industry Investments & Expansions: 08:30–09:15
Episode Recap: 09:15–end

Summary Tone

The episode maintains a brisk, factual, and optimistic tone, emphasizing both the challenges and the transformative potential of new biopharma developments.

For professionals and investors in life sciences, this episode provides a concise yet thorough look at the current state of pharma and biotech—from vaccine hesitancy’s industry-wide effects to the promising frontiers in obesity, cancer, biosimilars, and global vaccine manufacturing collaborations.

Loading summary...

Transcript

A (0:00)

Biotech Daily is now open for sponsors and Job of the Week listings. If you want to reach biotech or pharma operators, scientists, founders and investors, you can book a single episode, a full week or promote an open role, all directly by visiting sponsor O with AI that's sponsor owith AI.

B (0:19)

Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today we delve into a landscape marked by significant scientific advancements, regulatory challenges and strategic investments that are shaping the future of healthcare. Let's begin with Moderna's recent decision to halt its late stage vaccine trials, a move reflective of a broader trend of vaccine hesitancy in the United States. Moderna's CEO Stefan Bansal pointed to shifts in government policy and an increasing public skepticism towards vaccines as pivotal reasons for this decision. This development signals a potential slowdown in vaccine research and development investments across the industry. The implications are profound, as vaccine hesitancy could impact public health initiatives and the readiness to tackle future pandemics in parallel. Developments Sanofi is navigating its own set of challenges with its eczema treatment. Despite plans to file for FDA approval for its OX40 blocker following the phase 3 COAST 2 trial reactions, results were mixed, echoing earlier data that analysts found underwhelming. This situation highlights the inherent uncertainties in drug development and raises questions about the treatment's potential market success. As Sanofi persists, the broader industry is reminded of the complexities involved in bringing new therapies to market, particularly in dermatology, where unmet needs remain significant. Meanwhile, Chinese biotech firm Corexyl has secured an impressive $287 million in Series D1 funding to push forward its oral GLP1 therapy. This funding will support its mid stage development in the US and preparations for phase three studies. The investment underscores a robust interest in GLP1 therapies, known for their efficacy in treating type 2 diabetes and obesity. The competitive landscape for these therapies is heating up, with major players vying for market dominance through novel delivery mechanisms and enhanced patient outcomes. Notably, Novo Nordisk's Oral Wegovy is advancing, while Eli Lilly's orfordlipron faces delays, highlighting the strategic importance of timely development and market entry in capturing lucrative opportunities within this therapeutic area. On the regulatory front, a notable legislative challenge has emerged with the failure to reauthorize the FDA's Rare Pediatric Disease Priority Review Voucher program for 2024. Advocates are calling for its reinstatement given its critical role in incentivizing the development of rare disease treatments through expedited review processes. Such regulatory changes underscore the delicate balance between encouraging innovation and ensuring rigorous standards, a dynamic that continuously shapes R and D strategies within the industry. In oncology, Bristol Myers Squibb is making headlines with an $850 million investment in Janix Therapeutics Tumor Activated Drugs. This significant investment reaffirms BMS's commitment to pioneering cancer therapies that promise better patient outcomes through innovative mechanisms of action. The focus on oncology reflects a broader industry trend towards precision medicine and targeted treatments aimed at improving efficacy while minimizing side effects. As we pivot to manufacturing developments, Lott Biologics is expanding its capabilities with plans to launch its Syracuse ADC hub by 2026. This expansion aligns with global efforts to enhance manufacturing quality and capacity, crucial factors as biopharmaceuticals become more complex and demand increases. Turning our attention to financial achievements within the industry, Samsung Biologics has reached a historic milestone by becoming the first Korean biopharmaceutical company to surpass a profit threshold of 2 trillion won. This accomplishment spotlights the growing influence of contract manufacturing organizations like Samsung Biologics in driving efficiencies and innovation within biologics production, a sector increasingly central to modern therapeutics. The biosimilars market is poised for transformative growth as well, with Sandoz identifying a $322 billion opportunity over the next decade as numerous biologic patents expire. This golden decade for biosimilars promises enhanced accessibility and affordability of biologic therapies, marking a pivotal period for companies aiming to capture significant market share. Precision medicine continues to gain traction as Gardent Health and Pfizer secure FDA approval for Gardent360, a companion diagnostic targeting BRAF v600e mutations in metastatic colorectal cancer. This approval emphasizes the critical role of precision diagnostics in personalizing cancer treatment regimens based on genetic profiles. Collaborative efforts remain vital in tackling global health challenges, as seen with CEPI's partnership with Merck Co. And SK Bioscience on a $30 million project focused on Ebola vaccine manufacturing. Such alliances harness collective expertise and resources to accelerate vaccine development. Key strategies amidst ongoing public health threats, Clinical trials are yielding promising results, too. Corcept Therapeutics Relicoralent has shown an overall survival benefit in phase 3 trials for patients with platinum resistant ovarian cancer, while Hough Therapeutics reports positive phase 2 outcomes with HT001 for managing EGFR inhibitor induced skin toxicities. These findings contribute valuable insights into managing complex cancer cases resistant to conventional therapies. Investment flows remain robust as companies like Corexyl Pharmaceuticals raise substantial capital to advance obesity treatments, while Pac Therapeutics secures $77 million for crass driven cancer therapy research. These funding rounds reflect investor confidence in innovative approaches addressing major health challenges such as obesity and cancer. Strategic expansions are also on the agenda, with W Medicine planning to extend its diabetes drug Dorzaliad and beyond China into broader Asian markets, a move aimed at tackling metabolic diseases more effectively across diverse populations. In summation, these developments highlight a dynamic pharmaceutical and biotech landscape characterized by scientific breakthroughs, regulatory shifts, increased competition from biosimilars, and strategic collaborations, all holding significant potential for advancing patient care globally while driving innovation within drug development. Thank you for listening to Pharma Daily. Stay informed with us as we navigate these complex yet exciting times in pharmaceuticals and biotechnology, where each breakthrough holds promise for better health outcomes worldwide.